Amgen Inc. is a biotechnology company that develops innovative therapies to treat serious diseases and improve patient lives globally.
Amgen Inc. is a leading biotechnology company that specializes in the discovery, development, manufacturing, and delivery of innovative medicines aimed at addressing severe diseases and high unmet medical needs. The company operates primarily in the human therapeutics segment and has a robust pipeline of potential first-in-class medicines at various development stages. With operations spanning around 100 countries, Amgen has made significant strides in enhancing treatment efficacy for patients, thereby aiming to relieve both the social and economic burdens associated with diseases such as cancer, autoimmune disorders, and other rare conditions.
As part of its business strategy, Amgen has recently expanded its portfolio through the acquisition of Horizon Therapeutics, which strengthens its position in the rare disease market with products that target specific high-need therapy areas, like thyroid eye disease and chronic refractory gout. Amgen leverages its extensive research capabilities, biomanufacturing expertise, and established marketing distribution channels to provide its innovative therapies to healthcare providers and patients while focusing on continuous improvement in patient outcomes and drug accessibility globally.